Cross-Sector entity
Eli Lilly is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. The 54-day window averages about 0.6 stories each week. The busiest single day carried 2. clinical-trial accounts for 1 of the 5 tracked stories, while 4 other categories carry the remainder.
5 verified stories tracked
Last mentioned: May 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Eli Lilly is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. The 54-day window averages about 0.6 stories each week. The busiest single day carried 2. clinical-trial accounts for 1 of the 5 tracked stories, while 4 other categories carry the remainder. The tracked stories average 6.2 original sources each. Mounjaro appears in 5 tracked Cross-Sector stories published from March 13, 2026 through May 5, 2026. 20% of these stories carry negative sentiment.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mounjaro. Shared-story counts are live from our verified record — not editorial picks.
Publication of Articles
Two sources publish analyses on reasons to buy Eli Lilly stock, highlighting recent performance and future prospects
With Eli Lilly's stock up 25% year-to-date, investors are eyeing its strong financials and market position amid pharma sector growth. This development signals potential for high returns in finance circles, influenced by earnings and economic factors. Regulatory and market dynamics could shape future investment strategies in stocks like LLY.
Eli Lilly's innovative drug pipeline, including treatments for obesity and diabetes, positions it as a leader in biotech, with stock gains of 25% year-to-date signaling strong potential. For biotech professionals, this highlights the impact of clinical successes on market value and future R&D investments. Regulatory contexts like FDA approvals could further accelerate Eli Lilly's dominance in gene therapy and personalized medicine.
Source: fool.com · finance.yahoo.com
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 trial for type 2 diabetes. While the results are clinically significant, they appear to slightly trail the top-line efficacy of Lilly's own blockbuster Mounjaro, shifting the industry focus toward the drug's potential for superior weight loss.
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 diabetes trial, a result that matches or slightly trails the performance of its own blockbuster Mounjaro. While the glucose-lowering data is robust, the market's primary interest remains focused on the drug's potential for industry-leading weight loss and metabolic benefits.
Source: Endpoints News · Endpoints News
Eli Lilly has issued a formal warning regarding "potentially dangerous" impurities discovered in compounded versions of its tirzepatide-based medications, Mounjaro and Zepbound. The company’s internal testing revealed significant safety risks in off-brand formulations, intensifying the ongoing conflict between big pharma and compounding pharmacies.
